Essential Partners’s Harvard Bioscience HBIO Stock Holding History

Essential Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$39	–	2717
2025 Q2	$39	Buy	+9	New	+$38	﹤0.01%	2168

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.46B AUM 78.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Essential Partners's HBIO Position: Q3 2025 in Review

Essential Partners sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 9 shares — an estimated $39 sold.

Essential Partners first reported a position in HBIO in Q2 2025 and held it in 1 quarter. The position peaked at $39 in Q2 2025. 60 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

Essential Partners reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 9 Harvard Bioscience shares in Q3 2025, an estimated $39.
Essential Partners first reported a position in Harvard Bioscience in Q2 2025 and held it in 1 quarter.
Essential Partners's Harvard Bioscience position peaked at $39 in Q2 2025.
60 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.